Clinical trial
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease
NCT00072826 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00072826 |
|---|---|
| Title | Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease |
| Official title | Atorvastatin Therapy To Improve Endothelial Function in Sickle Cell Disease |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease |
| Intervention type | Drug |
| Interventions | Oxypurinol, L-NMMA, Acetylcholine |
| Enrollment | 44 |
| Start date | Nov 4, 2003 |
| Primary completion | Aug 24, 2007 |
| Completion | Aug 24, 2007 |
| First posted | Nov 11, 2003 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: